Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Argus Health
Daiichi Sankyo
Teva
Cantor Fitzgerald

Generated: March 23, 2019

DrugPatentWatch Database Preview

ZAVESCA Drug Profile

« Back to Dashboard

Which patents cover Zavesca, and when can generic versions of Zavesca launch?

Zavesca is a drug marketed by Actelion Pharms Ltd and is included in one NDA.

The generic ingredient in ZAVESCA is miglustat. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the miglustat profile page.

Drug patent expirations by year for ZAVESCA
Pharmacology for ZAVESCA
Synonyms for ZAVESCA
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
1,5-Dideoxy-1,5-N-butylimino-D-glucitol
134282-77-2
3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-
3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3r,4R,5S)-
3917AH
72599-27-0
AB00489939-10
AC1L1BHJ
ACN-025888
ADN3S497AZ
AKOS028109118
AN-010
API0003392
BC677641
BDBM18355
BICL4040
Brazaves
Brazaves (TN)
BuDNJ
Butyldeoxynojirimycin
CAS-72599-27-0
CHEBI:50381
CHEMBL1029
CS-2776
D-Glucitol, 1,5-(butylimino)-1,5-dideoxy-
D05032
DB00419
DSSTox_CID_25618
DSSTox_GSID_45618
DSSTox_RID_81006
DTXSID6045618
GTPL4841
HMS2090N20
HY-17020
LS-116261
MFCD00272581
Miglustat
Miglustat (JAN/USAN/INN)
Miglustat [USAN:INN:BAN]
Miglustat [USAN]
Miglustat, Hydrochloride
miglustatum
N-(n-Butyl)-1-deoxynojirimycin min. 99%
N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol
N-(n-Butyl)deoxynojirimycin
N-Bu-DNJ
n-Butyl deoxynojirimycin
n-Butyl dnj
N-butyl-1-deoxynojirimycin
N-Butyl-deoxynojirimycin
N-Butyl-DNJ
N-Butyldeoxynojirimycin
N-Butyldeoxynojirimycin, film (dried in situ)
N-Butylmoranoline
NB-DNJ
NBV
NCGC00018140-02
NCGC00024452-03
NCGC00024452-04
OGT 918
OGT-918
SB18741
SC 48334
SC-48334
SC48334
SCHEMBL246893
SR-01000000043
SR-01000000043-2
Tox21_110830
Tox21_110830_1
UNII-ADN3S497AZ
UQRORFVVSGFNRO-UTINFBMNSA-N
Vevesca
W-203639
Zavesca (TN)
ZINC3794711

US Patents and Regulatory Information for ZAVESCA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ZAVESCA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actelion Pharms Ltd ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 ➤ Sign Up ➤ Sign Up
Actelion Pharms Ltd ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Colorcon
Julphar
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.